Overbeck, Tobias R.

[["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Gauler, Thomas C."],["dc.contributor.author","Besse, Benjamin"],["dc.contributor.author","Meric, J. B."],["dc.contributor.author","Gounant, Valerie"],["dc.contributor.author","Fischer, B."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Krissel, Heiko"],["dc.contributor.author","Laurent, Dirk"],["dc.contributor.author","Soria, Jean-Charles"],["dc.contributor.author","Eberhardt, Wilfried E."],["dc.date.accessioned","2018-11-07T11:00:17Z"],["dc.date.available","2018-11-07T11:00:17Z"],["dc.date.issued","2007"],["dc.format.extent","S358"],["dc.identifier.doi","10.1097/01.JTO.0000283188.24297.13"],["dc.identifier.isi","000248688600274"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50887"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1556-0864"],["dc.title","Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Case Reports in Oncology"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Engelke, Christoph"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hugo, Sara"],["dc.contributor.author","Kellner, Laura"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.date.accessioned","2020-12-10T18:37:47Z"],["dc.date.available","2020-12-10T18:37:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1159/000444745"],["dc.identifier.eissn","1662-6575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77092"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Clinical Infectious Diseases"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Diering, Nina"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Gross, Uwe"],["dc.contributor.author","Grimbacher, Bodo"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2018-11-07T10:16:10Z"],["dc.date.available","2018-11-07T10:16:10Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1093/cid/ciw020"],["dc.identifier.isi","000374248700026"],["dc.identifier.pmid","26787170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40985"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1537-6591"],["dc.relation.issn","1058-4838"],["dc.title","Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Felip, Enriqueta"],["dc.contributor.author","Massuti, Bartomeu"],["dc.contributor.author","Maestre, Jose Antonio"],["dc.contributor.author","Alonso, Guillermo"],["dc.contributor.author","Paniagua, Jose Manuel R."],["dc.contributor.author","Gonzalez-Larriba, Jose Luis"],["dc.contributor.author","Camps, Carlos"],["dc.contributor.author","Isla, Dolores"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Costas, Emma"],["dc.contributor.author","Sanchez, Jose Javier"],["dc.contributor.author","Rosell, Rafael"],["dc.date.accessioned","2018-11-07T11:25:09Z"],["dc.date.available","2018-11-07T11:25:09Z"],["dc.date.issued","2009"],["dc.format.extent","S283"],["dc.identifier.isi","000269496000278"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56568"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","944"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","New England Journal of Medicine"],["dc.bibliographiccitation.lastpage","957"],["dc.bibliographiccitation.volume","383"],["dc.contributor.author","Wolf, Jürgen"],["dc.contributor.author","Seto, Takashi"],["dc.contributor.author","Han, Ji-Youn"],["dc.contributor.author","Reguart, Noemi"],["dc.contributor.author","Garon, Edward B."],["dc.contributor.author","Groen, Harry J.M."],["dc.contributor.author","Tan, Daniel S.W."],["dc.contributor.author","Hida, Toyoaki"],["dc.contributor.author","de Jonge, Maja"],["dc.contributor.author","Orlov, Sergey V."],["dc.contributor.author","Smit, Egbert F."],["dc.contributor.author","Souquet, Pierre-Jean"],["dc.contributor.author","Vansteenkiste, Johan"],["dc.contributor.author","Hochmair, Maximilian"],["dc.contributor.author","Felip, Enriqueta"],["dc.contributor.author","Nishio, Makoto"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Ohashi, Kadoaki"],["dc.contributor.author","Toyozawa, Ryo"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","de Marinis, Filippo"],["dc.contributor.author","Kim, Tae-Min"],["dc.contributor.author","Laack, Eckart"],["dc.contributor.author","Robeva, Anna"],["dc.contributor.author","Le Mouhaer, Sylvie"],["dc.contributor.author","Waldron-Lynch, Maeve"],["dc.contributor.author","Sankaran, Banu"],["dc.contributor.author","Balbin, O. Alejandro"],["dc.contributor.author","Cui, Xiaoming"],["dc.contributor.author","Giovannini, Monica"],["dc.contributor.author","Akimov, Mikhail"],["dc.contributor.author","Heist, Rebecca S."],["dc.date.accessioned","2021-04-14T08:23:04Z"],["dc.date.available","2021-04-14T08:23:04Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1056/NEJMoa2002787"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80794"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1533-4406"],["dc.relation.issn","0028-4793"],["dc.title","Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","81"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","83"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Claßen, Anna"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Perske, Christina"],["dc.contributor.author","Overbeck, Tobias"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Lippert, Undine"],["dc.date.accessioned","2020-12-10T18:27:17Z"],["dc.date.available","2020-12-10T18:27:17Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/ddg.13398"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76294"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Leukemia cutis in a patient with chronic myelomonocytic leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","864"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","871"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Daldrup, Benjamin"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:58:48Z"],["dc.date.available","2018-11-07T08:58:48Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose: To test for an association between high-grade acute organ toxicity during adjuvant radiation and chemotherapy and treatment outcome in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Institutional review board approval was obtained for this retrospective study. From September 1994 to October 2008, 294 HNSCC patients were treated with adjuvant radiation and chemotherapy at the authors' department. They received normofractionated (2 Gy per fraction) irradiation to include associated nodal drainage sites, for a cumulative dose of 60-64 Gy. From January 2002 to December 2009, 91 patients received additional concomitant cisplatin-based chemotherapy. Toxicity during treatment was monitored weekly according to the common toxicity criteria (CTC); any CTC toxicity grade 3 or higher, including mucositis, dysphagia, or skin reaction, was considered high-grade acute organ toxicity. The influence of possible prognostic factors on overall survival and locoregional control was studied by means of uni- and multivariate Cox regression. Results: A statistically significant association was found between high-grade acute organ toxicity and both overall survival and locoregional control. Patients with CTC grade 3 or greater acute organ toxicity had a 5-year overall survival and locoregional control rate of 90% and 97%, respectively, as compared with 24% and 74%, respectively, in patients without such toxicity (P < .01). Multivariate analyses revealed that this association was independent from other factors that may influence treatment toxicity, especially concomitant chemotherapy and/or radiation therapy. Conclusion: The data suggest that normal tissue and tumor tissue may behave similarly with respect to treatment response, as high-grade acute organ toxicity during radiation and chemotherapy was associated with better outcomes in the patient population; therefore, the hypothesis should be further analyzed on the biomolecular and clinical level and with other tumor entities in prospective clinical trials. (C)RSNA, 2011"],["dc.identifier.doi","10.1148/radiol.10100705"],["dc.identifier.isi","000287573100023"],["dc.identifier.pmid","21339350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23729"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.title","High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Adjuvant Radiation and Chemotherapy for Locally Advanced Head and Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Lung Cancer"],["dc.bibliographiccitation.volume","49"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schondube, F."],["dc.contributor.author","Schmidtberger, H."],["dc.contributor.author","Andreas, S."],["dc.contributor.author","Schirren, J."],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Keppler, U."],["dc.contributor.author","Leupold, H."],["dc.contributor.author","Baum, R."],["dc.date.accessioned","2018-11-07T09:26:18Z"],["dc.date.available","2018-11-07T09:26:18Z"],["dc.date.issued","2005"],["dc.format.extent","S26"],["dc.identifier.doi","10.1016/S0169-5002(05)80201-6"],["dc.identifier.isi","000231307800076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30268"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","11th World Conference on Lung Cancer"],["dc.relation.eventlocation","Barcelona, SPAIN"],["dc.relation.issn","0169-5002"],["dc.title","Phase II induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIB: FDG-PET response predicts overall and disease free survival"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","81"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cancer/Radiothérapie"],["dc.bibliographiccitation.lastpage","88"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Bloch, E."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Koerber, Wolfgang"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Mueller, M."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T08:57:24Z"],["dc.date.available","2018-11-07T08:57:24Z"],["dc.date.issued","2011"],["dc.description.abstract","Introduction. - Curative therapy for patients with small-cell lung cancer (SCLC) is based on multidrug chemotherapy combinations and radiotherapy. After a long time follow-up, the aim of the study was to evaluate the efficacy and toxicity of sequential chemo-radiotherapy and the effect of prophylactic cranial irradiation (PCI). Methods. - From 1995-2005, 96 patients with SCLC (64 limited-disease [LD], 32 extensive-disease [ED]: median age 61 years [range 39-79]) were treated at our department with varying chemotherapy regimens and sequential mediastinal radiotherapy (50 Gy + 10 Gy boost in case of residual disease after chemotherapy). Afterwards, 15 patients with LD, good general condition and at least partial response after local treatment received PCI (30 Gy). Results. - After a median follow-up of 78.6 months, 20 patients remained alive (20.8%, median survival time 18.2 months). The 2-/5-year overall survival rates were 33.8% and 12.6%, the 2-/5-year loco-regional control rates were 30.3% and 24.5%, respectively. Distant metastases occurred in 43 patients (24 cerebral). Cerebral metastasis occurred in 6.7% and 27.2% of the patients with PCI and without PCI respectively. Only tumor stage showed a statistically significant impact on overall survival and loco-regional control in multivariate analysis. Radiotherapy was well tolerated. Grade 3/4 toxicity occurred in seven patients. Prognosis of patients with SCLC remains poor. Administration of PCI in selected patients bears a decrease in the incidence of cerebral metastases. Alternative chemotherapy schemes as well as irradiation schemes and techniques should be the substance of future randomized trials. (C) 2010 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved."],["dc.identifier.doi","10.1016/j.canrad.2010.03.017"],["dc.identifier.isi","000289580700001"],["dc.identifier.pmid","20708424"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23393"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier"],["dc.relation.issn","1278-3218"],["dc.title","Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC - treatment results after long-term follow-up and literature overview"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Sebastian, Martin"],["dc.contributor.author","Serke, Monika Heidi"],["dc.contributor.author","Grohe, Christian"],["dc.contributor.author","Hillejan, Lars"],["dc.contributor.author","Passlick, Bernward"],["dc.contributor.author","Reinmuth, Nils"],["dc.contributor.author","Graeven, Ullrich"],["dc.contributor.author","Lueers, Anne C."],["dc.contributor.author","Radke, Susanne M."],["dc.contributor.author","Karatas, Aysun"],["dc.contributor.author","Tiemann, Markus"],["dc.contributor.author","Heukamp, Lukas"],["dc.contributor.author","Overbeck, Tobias R."],["dc.date.accessioned","2018-11-07T09:51:51Z"],["dc.date.available","2018-11-07T09:51:51Z"],["dc.date.issued","2015"],["dc.format.extent","S564"],["dc.identifier.isi","000370365102534"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35996"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","Induction Therapy with Intercalated TKI and Chemotherapy in NSCLC with Activating EGFR Mutation in Stages II-IIIB: NeoIntercal"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]